PLXP - Dipexium Pharmaceuticals Stock Price, News & Analysis

$6.65 -0.10 (-1.48 %)
(As of 11/23/2017 03:21 PM ET)
Previous Close$6.75
Today's Range$6.65 - $6.75
52-Week Range$5.60 - $22.00
Volume2,500 shs
Average Volume14,304 shs
Market Capitalization$58.86 million
P/E RatioN/A
Dividend YieldN/A
Beta1.86

About Dipexium Pharmaceuticals (NASDAQ:PLXP)

Dipexium Pharmaceuticals logoPLx Pharma Inc., formerly Dipexium Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is a late stage specialty pharmaceutical company focusing on commercializing its lead products: Aspertec 325 mg and Aspertec 81 mg (Aspertec). The Company's products and technology includes PLxGuard delivery system, Aspertec 325 mg, PL1100/PL1200 Ibuprofen. PLxGuard delivery system uses surface acting lipids, such as phospholipids and free fatty acids, to modify the physiochemical properties of various drugs to selectively release these drugs to targeted portions of the GI tract. The Company's lead product Aspertec 325 mg is a liquid-fill aspirin capsule for prevention of cardiovascular disease. Through PLxGuard delivery system the Company creates a lipid-based formulation of ibuprofen, PL1200 Ibuprofen Capsules, 200 mg.


Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PLXP
CUSIPN/A

Debt

Debt-to-Equity Ratio0.56%
Current Ratio8.99%
Quick Ratio8.88%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$1.40 per share
Price / Book4.75

Dividend

Annual DividendN/A
Dividend YieldN/A

Profitability

Trailing EPSN/A
Net Income$-21,320,000.00
Net MarginsN/A
Return on Equity-154.79%
Return on Assets-86.47%

Miscellaneous

Employees3
Outstanding Shares8,720,000

Frequently Asked Questions for Dipexium Pharmaceuticals (NASDAQ:PLXP)

What is Dipexium Pharmaceuticals' stock symbol?

Dipexium Pharmaceuticals trades on the NASDAQ under the ticker symbol "PLXP."

How were Dipexium Pharmaceuticals' earnings last quarter?

Dipexium Pharmaceuticals, Inc. (NASDAQ:PLXP) announced its quarterly earnings data on Monday, April, 17th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by $0.02. View Dipexium Pharmaceuticals' Earnings History.

Who are some of Dipexium Pharmaceuticals' key competitors?

Who are Dipexium Pharmaceuticals' key executives?

Dipexium Pharmaceuticals' management team includes the folowing people:

  • Rita M. O'Connor CPA, Chief Financial Officer (Age 49)
  • Robert G. Shawah CPA, Chief Accounting Officer, Treasurer (Age 49)
  • Steven Valentino, Vice President - Trade Sales
  • Tom Long, Vice President - Manufacturing & Technical Operations
  • Gary Balkema, Director
  • Kirk Calhoun, Director
  • Robert Casale, Director
  • Natasha Giordano, Director (Age 56)
  • John W. Hadden II, Director

When did Dipexium Pharmaceuticals IPO?

(PLXP) raised $68 million in an initial public offering on Thursday, February 4th 2016. The company issued 3,800,000 shares at $17.00-$19.00 per share. Raymond James acted as the underwriter for the IPO and Maxim Group LLC and Janney Montgomery Scott were co-managers.

Who owns Dipexium Pharmaceuticals stock?

Dipexium Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Harel Insurance Investments & Financial Services Ltd. (2.88%) and Susquehanna International Group LLP (1.74%). Company insiders that own Dipexium Pharmaceuticals stock include David Emerson Jorden, Gary L Mossman and Michael J Valentino. View Institutional Ownership Trends for Dipexium Pharmaceuticals.

Who sold Dipexium Pharmaceuticals stock? Who is selling Dipexium Pharmaceuticals stock?

Dipexium Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Susquehanna International Group LLP. View Insider Buying and Selling for Dipexium Pharmaceuticals.

Who bought Dipexium Pharmaceuticals stock? Who is buying Dipexium Pharmaceuticals stock?

Dipexium Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Harel Insurance Investments & Financial Services Ltd.. Company insiders that have bought Dipexium Pharmaceuticals stock in the last two years include David Emerson Jorden, Gary L Mossman and Michael J Valentino. View Insider Buying and Selling for Dipexium Pharmaceuticals.

How do I buy Dipexium Pharmaceuticals stock?

Shares of Dipexium Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Dipexium Pharmaceuticals' stock price today?

One share of Dipexium Pharmaceuticals stock can currently be purchased for approximately $6.65.

How big of a company is Dipexium Pharmaceuticals?

Dipexium Pharmaceuticals has a market capitalization of $58.86 million. Dipexium Pharmaceuticals employs 3 workers across the globe.

How can I contact Dipexium Pharmaceuticals?

Dipexium Pharmaceuticals' mailing address is 8285 EL RIO STREET SUITE 130, HOUSTON TX, 77054. The biotechnology company can be reached via phone at 713-842-1249 or via email at [email protected]


MarketBeat Community Rating for Dipexium Pharmaceuticals (PLXP)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  62 (Vote Outperform)
Underperform Votes:  83 (Vote Underperform)
Total Votes:  145
MarketBeat's community ratings are surveys of what our community members think about Dipexium Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Dipexium Pharmaceuticals (NASDAQ:PLXP)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 1 Buy Rating, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Analysts' Consensus Price Target: N/A

Consensus Price Target History for Dipexium Pharmaceuticals (NASDAQ:PLXP)

Price Target History for Dipexium Pharmaceuticals (NASDAQ:PLXP)

Analysts' Ratings History for Dipexium Pharmaceuticals (NASDAQ:PLXP)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/1/2017Redburn PartnersUpgradeOutperformLowView Rating Details
10/26/2016Raymond James Financial, Inc.DowngradeOutperform -> Mkt PerformN/AView Rating Details
10/25/2016Feltl & Co.DowngradeBuy -> HoldN/AView Rating Details
(Data available from 11/23/2015 forward)

Earnings

Earnings History and Estimates Chart for Dipexium Pharmaceuticals (NASDAQ:PLXP)

Earnings by Quarter for Dipexium Pharmaceuticals (NASDAQ:PLXP)

Earnings History by Quarter for Dipexium Pharmaceuticals (NASDAQ PLXP)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/17/2017Q1 2017($0.12)($0.14)ViewN/AView Earnings Details
11/10/2016Q3 2016($0.45)($0.45)ViewN/AView Earnings Details
8/3/2016Q216($0.54)($0.52)ViewN/AView Earnings Details
5/11/2016Q116($0.52)($0.56)ViewListenView Earnings Details
11/13/2015Q315($0.47)($0.49)ViewListenView Earnings Details
8/13/2015Q215($0.43)($0.47)ViewListenView Earnings Details
5/14/2015Q115($0.44)($0.49)ViewListenView Earnings Details
4/14/2015($0.44)($0.38)ViewN/AView Earnings Details
3/24/2015Q414$0.52($0.38)ViewN/AView Earnings Details
11/12/2014Q3 2014($0.49)($0.45)ViewN/AView Earnings Details
8/12/2014Q2 2014($0.37)($0.46)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Dipexium Pharmaceuticals (NASDAQ:PLXP)
Current Year EPS Consensus Estimate: $-1.71 EPS
Next Year EPS Consensus Estimate: $-2.02 EPS

Dividends

Dividend History for Dipexium Pharmaceuticals (NASDAQ:PLXP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Dipexium Pharmaceuticals (NASDAQ PLXP)

Insider Ownership Percentage: 47.70%
Institutional Ownership Percentage: 22.83%
Insider Trades by Quarter for Dipexium Pharmaceuticals (NASDAQ:PLXP)
Insider Trades by Quarter for Dipexium Pharmaceuticals (NASDAQ:PLXP)

Insider Trades by Quarter for Dipexium Pharmaceuticals (NASDAQ PLXP)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/14/2017David Emerson JordenCFOBuy32,727$6.88$225,161.76View SEC Filing  
6/14/2017Gary L MossmanCOOBuy7,273$6.88$50,038.24View SEC Filing  
6/14/2017Michael J ValentinoInsiderBuy29,091$6.88$200,146.08View SEC Filing  
5/21/2014Jack H DeanDirectorBuy3,000$9.00$27,000.00View SEC Filing  
3/18/2014David GarrettVPBuy2,083$12.00$24,996.00View SEC Filing  
3/18/2014Thomas L HarrisonDirectorBuy2,000$12.00$24,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Dipexium Pharmaceuticals (NASDAQ PLXP)

Source:
DateHeadline
Is PLx Pharma Inc’s (PLXP) Balance Sheet Strong Enough To Weather A Storm?Is PLx Pharma Inc’s (PLXP) Balance Sheet Strong Enough To Weather A Storm?
finance.yahoo.com - November 22 at 6:43 AM
Dipexium Pharmaceuticals, Inc. (PLXP) Cut to Sell at Zacks Investment ResearchDipexium Pharmaceuticals, Inc. (PLXP) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - November 18 at 8:18 PM
Zacks: Analysts Set $12.00 Target Price for Dipexium Pharmaceuticals, Inc. (PLXP)Zacks: Analysts Set $12.00 Target Price for Dipexium Pharmaceuticals, Inc. (PLXP)
www.americanbankingnews.com - November 13 at 3:03 PM
PLx Pharma Inc. Reports Third Quarter 2017 ResultsPLx Pharma Inc. Reports Third Quarter 2017 Results
finance.yahoo.com - November 12 at 11:44 AM
PLx Pharma reports 3Q lossPLx Pharma reports 3Q loss
finance.yahoo.com - November 12 at 11:44 AM
PLx Pharma, Inc. to Host Earnings CallPLx Pharma, Inc. to Host Earnings Call
finance.yahoo.com - November 12 at 11:44 AM
PLx Pharma Inc. to Discuss 2017 Third Quarter Financial Results on November 10, 2017 Conference CallPLx Pharma Inc. to Discuss 2017 Third Quarter Financial Results on November 10, 2017 Conference Call
finance.yahoo.com - November 4 at 8:55 AM
Dipexium Pharmaceuticals, Inc. (PLXP) Upgraded at Zacks Investment ResearchDipexium Pharmaceuticals, Inc. (PLXP) Upgraded at Zacks Investment Research
www.americanbankingnews.com - October 15 at 12:16 PM
 Dipexium Pharmaceuticals, Inc. (PLXP) Given Consensus Rating of "Buy" by Brokerages Dipexium Pharmaceuticals, Inc. (PLXP) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - October 14 at 2:18 AM
Dipexium Pharmaceuticals (PLXP) & ZIOPHARM Oncology (ZIOP) Head-To-Head ComparisonDipexium Pharmaceuticals (PLXP) & ZIOPHARM Oncology (ZIOP) Head-To-Head Comparison
www.americanbankingnews.com - October 2 at 8:14 PM
PLx Pharma Present at the Sidoti & Company Fall 2017 ConferencePLx Pharma Present at the Sidoti & Company Fall 2017 Conference
finance.yahoo.com - September 19 at 6:33 AM
PLx Pharma Retains Dr. Efthymios N. Deliargyris as Chief Medical AdvisorPLx Pharma Retains Dr. Efthymios N. Deliargyris as Chief Medical Advisor
finance.yahoo.com - September 13 at 7:49 AM
Head-To-Head Survey: Dipexium Pharmaceuticals (PLXP) and Kindred Biosciences (KIN)Head-To-Head Survey: Dipexium Pharmaceuticals (PLXP) and Kindred Biosciences (KIN)
www.americanbankingnews.com - August 21 at 4:24 PM
PLx Pharma Inc. Reports Second Quarter 2017 ResultsPLx Pharma Inc. Reports Second Quarter 2017 Results
finance.yahoo.com - August 11 at 7:36 AM
PLx Pharma reports 2Q lossPLx Pharma reports 2Q loss
finance.yahoo.com - August 11 at 7:36 AM
Dipexium Pharmaceuticals, Inc. (PLXP) Rating Increased to Outperform at Redburn PartnersDipexium Pharmaceuticals, Inc. (PLXP) Rating Increased to Outperform at Redburn Partners
www.americanbankingnews.com - August 1 at 3:56 PM
Dipexium Pharmaceuticals, Inc. (PLXP) Upgraded by Raymond James Financial, Inc. to "Outperform"Dipexium Pharmaceuticals, Inc. (PLXP) Upgraded by Raymond James Financial, Inc. to "Outperform"
www.americanbankingnews.com - July 31 at 5:30 PM
UBS AG Upgrades Dipexium Pharmaceuticals, Inc. (PLXP) to "Outperform"UBS AG Upgrades Dipexium Pharmaceuticals, Inc. (PLXP) to "Outperform"
www.americanbankingnews.com - July 31 at 4:28 PM
 Dipexium Pharmaceuticals, Inc. (PLXP) Receives Consensus Rating of "Hold" from Analysts Dipexium Pharmaceuticals, Inc. (PLXP) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - July 24 at 8:22 PM
Money Makers: Houston pharma co., construction company file multimillion-dollar raisesMoney Makers: Houston pharma co., construction company file multimillion-dollar raises
www.bizjournals.com - July 8 at 11:46 PM
Protalix BioTherapeutics (PLX) CEO Moshe Manor on Q1 2017 Results - Earnings Call TranscriptProtalix BioTherapeutics' (PLX) CEO Moshe Manor on Q1 2017 Results - Earnings Call Transcript
seekingalpha.com - May 12 at 8:18 AM
BRIEF-Rita OConnor appointed CFO of PLx PharmaBRIEF-Rita O'Connor appointed CFO of PLx Pharma
www.reuters.com - May 2 at 5:04 PM
PLx Pharma Inc. (PLXP) Names Rita O’Connor as CFOPLx Pharma Inc. (PLXP) Names Rita O’Connor as CFO
www.streetinsider.com - May 2 at 5:04 PM

Social Media

Financials

Chart

Dipexium Pharmaceuticals (NASDAQ PLXP) Chart for Thursday, November, 23, 2017
Loading chart…

This page was last updated on 11/23/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.